health@hand LLC

Founded: 2017
1-2 employees
Stage: Prototype/ MVP
Sales: Working on it
health@hand recognizes that people do not want to take medicines and physicians do not want to prescribe pills, particularly when healthy living can have a similar impact without the side effects or cost. health@hand's goals are to help patients partner with their healthcare providers to: (1) prevent the need for starting medicine to lower high blood pressure and high blood sugar in patients with pre-hypertension/early hypertension and pre-diabetes/early diabetes (2) reduce/stop medications for high blood pressure and blood sugar through weight loss/lifestyle change coupled with home monitoring of blood pressure, blood sugar, and weight—the app/website tools also help patients and their providers increase/re-start medications during periods of weight re-gain, to prevent organ damage from high blood pressure/blood sugar which have no symptoms (3) identify prescription medications associated with weight gain/increased appetite and weight loss/appetite loss, including opportunities for drug-class switching to optimize weight-loss efforts. health@hand's innovative technology is supported by years of work, research, and analyses performed by founder Dr. Turer/collaborators regarding (1) the amount of weight loss needed to reduce the dose and number of anti-hypertensive and diabetes medications, and (2) use of medical technologies that allow home monitoring of weight, blood pressure, and blood sugar.
Company Contacts
Address:

MC 9063 - 5323 Harry Hines Blvd.

Dallas, TX

US 75390

Contact Us:
(214) 648-8801
Social Links:
Connect With Us
Contact Person
Related Communities

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.